-
Professor Chen Junqiang: Global esophageal cancer patients in China accounted for half, immunotherapy to break the many years of difficulties!
Time of Update: 2021-01-04
Professor Chen Junqiang: The contents include: (1) the prevention of the cause of chest tumors, regular key examinations of high-risk groups, etc., in order to achieve early detection, early diagnosis and early treatment, improve the survival rate of patients and reduce the cost of treatment.
-
Cynda Beval bead monoantin is approved in China for the treatment of relapsed glioblastoma
Time of Update: 2021-01-04
On December 28th Thyda Bio, a biopharmaceutical company dedicated to the development, production and marketing of innovative drugs for major diseases such as cancer, metabolic diseases and autoimmunity, announced that its self-developed recombinant anti-VEGF humanized monoclonal antibody drug is at stake (Beva Pearl Monomass, International Trademark: Byvasda has been officially approved by China's State Drug Administration (NMPA) for the treatment of adult relapsed glioblastoma (GBM), the third adaptation approved by Dayo.
-
The first annual conference on cancer prevention and treatment in China was held in Beijing in 2020
Time of Update: 2021-01-04
In order to practice Health China Action and help cancer prevention and control work, on December 26, the launch ceremony of the 2020 First Annual Conference on Cancer Prevention and Control in China
-
Bio Valley Recommendation: Top10, a must-see heavy-weight study from November to December
Time of Update: 2021-01-03
Doi:10.1126/scitranslmed.abb5817 In a recent study published in the international journal Science Translational Medicine, scientists from the United States, Germany and other countries have jointly found that natural stress hormones may reactivate dormant cancer cells in mouse bodies, and that the results may help develop new treatments for cancer.
-
November-December Nature magazine had to look at the heavyweight highlights study
Time of Update: 2021-01-03
doi:10.1038/s41586-020-2971-8 Recently, an article published in the international magazine Nature entitled "The gut microbiota is associated with immune cell" In the study, scientists from institutions such as memorial Sloan Kettering Cancer Center revealed a link between the body's microbiome and the immune system, and for the first time found that changes in the concentration of different types of immune cells in the blood were directly related to the presence of different bacteri groups in the gut.
-
Glycine in tumors is used as a marker for MRS detection of gliomas
Time of Update: 2021-01-03
researchers used MRS to detect glycine, 2-hydroxypropypyt acid (2HG) and other tumor-related metabolites in 35 glioma patients; Levels of glycine and 2HG expression in prosurromas (Figure 1), tumor proliferation and progression increased when glycine content increased (Figure 2), and high glycine/2HG ratios indicated poor survival prognosis in patients (Figure 3).
-
"China's lymphoma patients throughout the management of quality control standards" issued in Beijing, to solve the needs of patients
Time of Update: 2021-01-03
To implement the State Council's Action Plan for Further Improvement of Medical Services, promote the "Healthy China 2030 Plan" to achieve a 15% increase in the overall cancer survival rate over the
-
BCMA CAR-T Cell Therapy! Johnson/Nanjing Legend cilta-cel submits rolling listing application in the United States: Treatment of multiple myeloma!
Time of Update: 2021-01-03
May 2018, based on the results of the LEGEND-2 study, Jansen initiated a Phase IB/II trial (NCT03548207) to assess the efficacy and safety of JNJ-4528's treatment of recurring or refracectable multiple myeloma in adults.
-
The antimalarial drug 芴 to treat GBM that resists radiotherapy and tymoamine
Time of Update: 2021-01-03
Conclusion This study review shows that HSPB1 and Fli-1 play an important role in regulating GBM against radiotherapy/thymosamine, and in-body and animal model experiments, it is shown that lubefantine targets EMT and ECM reshaping signaling axis mediated by Fli-1/HSPB1, providing a new treatment that can be used to treat glioblastoma of anti-radiation therapy/tymoamine.
-
Lenzilumab prevents or treats cytokine storms and neurotoxicity associated with CAR-T cell therapy
Time of Update: 2021-01-02
patent covers the use of lenzilumab for the prevention or treatment of cytokine release syndrome (CRS) and neurotoxicity in patients treated with CAR-T cells.
-
Br J Cancer: Tumor-Free Distance (TFD): A new prognostic indicator for early cervical cancer patients
Time of Update: 2021-01-02
Prognostic markers for early cervical cancer can be used to adjust the type of surgery in patients, including lymph node stages, types of hysterectomy, and, most importantly, complementary treatment applications.
-
Nat Commun: Multigene risk assessment for breast cancer
Time of Update: 2021-01-02
previous studies have shown that a multigene risk score (PRS) for breast cancer has the potential to improve risk prediction in patients, but information about its effectiveness in a variety of clinical situations remains limited.
-
Amgen submitted a listing application to EMA for the treatment of non-small cell lung cancer with the KRAS inhibitor sotorasib
Time of Update: 2021-01-02
amgen has filed a listing application with the European Medicines Agency (EMA) seeking approval for the therapeutic treatment of KRAS G12C mutant non-small cell lung cancer (NSCLC), a research KRAS inhibitor.
-
The latest CRISPR/Cas research advances in December 2020
Time of Update: 2021-01-02
In a new study, researchers at the University of California, Berkeley, have developed an easy way to do this, allowing anyone to analyze cells, including human cells, and quickly determine the DNA sequences in the genome that regulate the expression of specific genes.
-
NK cell joints (TriKE™ treat breast and gastrointestinal cancers
Time of Update: 2021-01-02
immuno-oncology company GT Biopharma announced today that it has filed a U.S. and international patent application and has initiated clinical development of NK Cell Joint (TriKE™) to treat HER2 plus, HER3 plus and HER2 plus / HER3 plus breast and gastrointestinal cancer.
-
Br J Cancer: SBI-756 and venetoclax: a new combination of B-cell lymphoma treatments
Time of Update: 2021-01-02
the study, researchers tested the sensitivity of cap-dependent mRNA translation inhibitors to the apoptosis effects of DLBCL and sleeve lymphoma (MCL).
SBI-756 blocks eIF4E-eIF4G interactions and cap-dependent translation Researchers have found that Venetoclax combined with SBI-756 to process DLBCL and MCL cells to induce apoptosis and enhance The effectiveness of Venetoclax.
-
The European Union has approved ® (yew alcohol beam) for the treatment of platinum-sensitive endoskine cancer
Time of Update: 2021-01-01
biopharmaceutical company Elevar Therapeutics announced today that its Apealea® (Yew alcohol beam) has been authorized by European regulators to be used in the European Economic Area in partnership with capratin for the treatment of adult patients with platinum-sensitive epitheliotic, primary peritiotic and fallopian tube cancers that have relapsed for the first time.
-
The SNDA for LORBRENA's treatment of previously untreated APK-positive lung cancer has been given priority by the FDA
Time of Update: 2021-01-01
In fact, it has been previously reported that the new generation of lung cancer target drug Loratini: significantly improved progression-free survival of ALC-positive NSCLC patients LORBRENA is a third-generation ALC inhibitor specifically developed to inhibit the most common tumor mutations, these mutations drive resistance to current drugs, up to 40% of ALC-positive lung cancer patients have brain metastasis.
-
Patient recruitment: Recombinant humanized anti-PD-1 monoclonal antibody (HX008) combined chemotherapy compared to Pabli-Pearl mono-anti-combination chemotherapy as a first-line treatment of advanced or metastasis non-squamous non-small cell lung cancer (NSCLC) phase II/III clinical studies
Time of Update: 2021-01-01
Basic information registration number CTR20202387 test status in the applicant contact Wang Liyan first public information date 2020-11-26 applicant name Taizhou Han Zhong Biopharmaceutical Co., Ltd.
-
Br J Cancer: The therapeutic effect of the drug RO6870810 on patients with NUT midline cancer, other solid tumors, or diffuse large B-cell lymphoma
Time of Update: 2021-01-01
in the RO6870810 Phase 1 study, the researchers treated patients with NC, other solid tumors, or DLBCL with 28 or 21 days of one-day treatment for 21 or 14 consecutive days of sethesic injections.
